ReviewCellular and molecular life sciences : CMLS2019
The role of endogenous tissue-type plasminogen activator in neuronal survival after ischemic stroke: friend or foe?
Review in Cellular and molecular life sciences : CMLS, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 33 citations in OpenAlex.
- Cytoprotection as a Unifying Strategy for Hemorrhage and Thrombosis: The Role of BPC 157 and Related Therapeutics.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Abrupt formation and spontaneous resolution of a mobile right atrial thrombus following intraoperative cardiopulmonary resuscitation during da Vinci robotic-assisted surgery: a case report.International journal of emergency medicine · 2025Article
- Thrombolysis for acute ischaemic stroke: development and update.Brain communications · 2025Review
- Anti-stroke biologics: from recombinant proteins to stem cells and organoids.Stroke and vascular neurology · 2024Review
- The role of neutrophils in tPA thrombolysis after stroke: a malicious troublemaker.Frontiers in immunology · 2024Review
- Tissue-type plasminogen activator (tPA) homozygous Tyr471His mutation associates with thromboembolic disease.MedComm · 2023Article
- Protection against brain injury after ischemic stroke by intravenous human amnion epithelial cells in combination with tissue plasminogen activator.Frontiers in neuroscience · 2023Article
- Statins and Hemostasis: Therapeutic Potential Based on Clinical Evidence.Advances in experimental medicine and biology · 2023Review
- Parvalbumin interneuron-derived tissue-type plasminogen activator shapes perineuronal net structure.BMC biology · 2022Article
- Proteomic Biomarkers of the Apnea Hypopnea Index and Obstructive Sleep Apnea: Insights into the Pathophysiology of Presence, Severity, and Treatment Response.International journal of molecular sciences · 2022Article
- Elevated plasma syndecan-1 as glycocalyx injury marker predicts unfavorable outcomes after rt-PA intravenous thrombolysis in acute ischemic stroke.Frontiers in pharmacology · 2022Article
- Review of evidence implicating the plasminogen activator system in blood-brain barrier dysfunction associated with Alzheimer's disease.Ageing and neurodegenerative diseases · 2022Article
- Might life-threatening acute pulmonary edema occur after using recombinant tissue plasminogen activator? A case report.BMC neurology · 2021Article
- Identification of Human Kinin-Forming Enzyme Inhibitors from Medicinal Herbs.Molecules (Basel, Switzerland) · 2021Article
- Low Expression of PLAT in Breast Cancer Infers Poor Prognosis and High Immune Infiltrating Level.International journal of general medicine · 2021Article
- Influence of Onset to Imaging Time on Radiological Thrombus Characteristics in Acute Ischemic Stroke.Frontiers in neurology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Endogenous protease tissue-type plasminogen activator (tPA) has highly efficient fibrinolytic activity and its recombinant variants alteplase and tenecteplase are established as highly effective thrombolytic drugs for ischemic stroke. Endogenous tPA is constituted of five functional domains through which it interacts with a variety of substrates, binding proteins and receptors, thus having enzymatic and cytokine-like effects to act on all cell types of the brain. In the past 2 decades, numerous studies have explored the clinical relevance of endogenous tPA in neurological diseases, especially in ischemic stroke. tPA is released from many cells within the brain parenchyma exposed to ischemia conditions in vitro and in vivo, which is believed to control neuronal fate. Some studies proved that tPA could induce blood-brain barrier disruption, neural excitotoxicity and inflammation, while others indicated that tPA also has anti-excitotoxic, neurotrophic and anti-apoptotic effects on neurons. Therefore, more work is needed to elucidate how tPA mediates such opposing functions that may amplify tPA from a therapeutic means into a key therapeutic target in endogenous neuroprotection after stroke. In this review, we summarize the biological characteristics and pleiotropic functions of tPA in the brain. Then we focus on possible hypotheses about why and how endogenous tPA mediates ischemic neuronal death and survival. Finally, we analyze how endogenous tPA affects neuron fate in ischemic stroke in a comprehensive view.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.